| Name | Title | Contact Details |
|---|
BMW of Buena Park is one of the largest and most popular BMW dealerships in the Buena Park area. Our dealership features an extensive inventory of new and pre-owned BMW vehicles for sale, exclusive BMW lease specials and financing offers, a state-of-the-art service center, and an experienced team of BMW enthusiasts ready to assist you with any request you may have.
RCB Bank Ltd, based in Cyprus, was established in 1995 and is known for enhancing economic ties between Russia and Europe. Originally named Russian Commercial Bank (Cyprus) Limited, it received its banking license from the Central Bank of Cyprus. The bank offers a range of typical commercial banking services, likely including corporate and retail banking, investment services, and international transactions. RCB Bank Ltd has expanded its presence in Cyprus with branches in Limassol and Nicosia. RCB Bank, located in Claremore, Oklahoma, was founded in 1936 and has grown to become one of the largest Oklahoma-owned banks. It provides personal and business banking services, loans, and investment products across over 50 locations in Oklahoma and Kansas. The bank emphasizes building strong relationships with its customers and actively participates in community events.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.